|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:antidote
|
gptkb:flumazenil
|
|
gptkbp:approvalYear
|
1985
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CD08
|
|
gptkbp:brand
|
gptkb:Versed
gptkb:Dormicum
|
|
gptkbp:broadcastOn
|
Schedule IV (US)
|
|
gptkbp:CASNumber
|
59467-70-8
|
|
gptkbp:category
|
benzodiazepine
anticonvulsant
muscle relaxant
hypnotic
|
|
gptkbp:chemicalFormula
|
C18H13ClFN3
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
acute narrow-angle glaucoma
severe respiratory insufficiency
|
|
gptkbp:controlledSubstanceSchedule
|
yes
|
|
gptkbp:developedBy
|
gptkb:Switzerland
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:eliminationHalfLife
|
1.5–2.5 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:firstSynthesized
|
1975
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Midazolam
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
325.8 g/mol
|
|
gptkbp:overdoseTreatment
|
gptkb:flumazenil
supportive care
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
4192
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
intranasal
buccal
|
|
gptkbp:sideEffect
|
gptkb:center
drowsiness
hypotension
respiratory depression
paradoxical reactions
|
|
gptkbp:solubility
|
water soluble (as hydrochloride salt)
|
|
gptkbp:UNII
|
R60L0SM5BC
|
|
gptkbp:usedFor
|
anesthesia induction
procedural sedation
sedation
seizure control
anxiety management
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Benzodiazepines
|
|
gptkbp:bfsLayer
|
6
|